Iván R. González: Does neoadjuvant immunotherapy outperform chemotherapy in resectable lung cancer?
Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, posted on X about recent paper by Mark M. Awad et al., titled “Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer” published on Journal of Clinical Oncology.
Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, Mariano Provencio Pulla
“Revolution in resectable lung cancer treatment: Does neoadjuvant immunotherapy outperform chemotherapy?
Important results:
- Median EFS: 54.8 months with immunotherapy vs. 20.9 months with chemotherapy. 3-year rates: 56% vs. 44%.
- OS: 3-year rates: 73% with immunotherapy vs. 61% with chemotherapy.
- Pathological complete response: Nivolumab + ipilimumab: 20.4% vs. 4.6% with chemotherapy.
- Toxicity: Grade 3-4 events: 14% with immunotherapy vs. 36% with chemotherapy.
Nivolumab + ipilimumab in the neoadjuvant setting delivers superior EFS and OS and demonstrates lower toxicity, marking a significant leap toward safer and more effective treatments.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023